Biomarkers for Immune Checkpoint Inhibitor Response in NSCLC: Current Developments and Applicability

Lung cancer has the highest mortality rate among all cancer types, resulting in over 1.8 million deaths annually. Immunotherapy utilizing immune checkpoint inhibitors (ICIs) has revolutionized the treatment of non-small cell lung cancer (NSCLC). ICIs, predominantly monoclonal antibodies, modulate co...

Descripción completa

Detalles Bibliográficos
Autores principales: Tostes, Katiane, Siqueira, Aléxia Polo, Reis, Rui Manuel, Leal, Leticia Ferro, Arantes, Lidia Maria Rebolho Batista
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10418476/
https://www.ncbi.nlm.nih.gov/pubmed/37569262
http://dx.doi.org/10.3390/ijms241511887

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10418476/
https://www.ncbi.nlm.nih.gov/pubmed/37569262
http://dx.doi.org/10.3390/ijms241511887

Ejemplares similares